Farnesol analogs, along with their related products (e.g., treatment compositions, wipes, absorbent articles, etc.) and their methods of formation, are provided. The farnesol analog includes a hydrophilic end group (e.g., a hydroxyl end group or a carboxylic acid end group) attached to farnesol via a covalent linkage (e.g., an ester group or an ether group).
